Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Alexa B. Kimball, Magdalena B. Wozniak et al.|Dermatology and Therapy|2025Cited by 2
64674 The impact of continuous secukinumab treatment through week 104 on patient reported outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trialsAlexa B. Kimball, Jacek C. Szepietowski, D. Ioannides et al.|Journal of the American Academy of Dermatology|2025Cited by 0